(Total Views: 654)
Posted On: 10/30/2024 8:57:56 AM
Post# of 153778
Quote:
Dr. Palmer will work with the CytoDyn team to oversee the two follow-up studies with SMC. These studies will again compare leronlimab alone and in combination with other therapies, including both resmetirom, the only approved treatment for MASH, and a GLP-1 agonist in an increased number of mice evaluated in both a proprietary STAM model of MASH which includes T2DM (previously studied), as well as a second model of liver fibrosis driven by CCL4 toxicity that is independent of fat deposition.
Getting all the background work done to show what leronlimab is capable of.
(19)
(0)
